$2.57T
Total marketcap
$178.2B
Total volume
BTC 49.99%     ETH 15.83%
Dominance

Denali Therapeutics DNLI Stock

20.09 USD {{ price }} -0.198703% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
2.8B USD
LOW - HIGH [24H]
19.77 - 20.6 USD
VOLUME [24H]
938.51K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-1.06 USD

Denali Therapeutics Price Chart

Denali Therapeutics DNLI Financial and Trading Overview

Denali Therapeutics stock price 20.09 USD
Previous Close 32.47 USD
Open 32.19 USD
Bid 0 USD x 900
Ask 0 USD x 800
Day's Range 31.07 - 32.68 USD
52 Week Range 21.64 - 39.43 USD
Volume 621.92K USD
Avg. Volume 741.89K USD
Market Cap 4.45B USD
Beta (5Y Monthly) 1.319014
PE Ratio (TTM) N/A
EPS (TTM) -1.06 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 58.5 USD

DNLI Valuation Measures

Enterprise Value 3.22B USD
Trailing P/E N/A
Forward P/E -9.444768
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 43.833942
Price/Book (mrq) 4.595474
Enterprise Value/Revenue 31.698
Enterprise Value/EBITDA -8.537

Trading Information

Denali Therapeutics Stock Price History

Beta (5Y Monthly) 1.319014
52-Week Change 35.94%
S&P500 52-Week Change 20.43%
52 Week High 39.43 USD
52 Week Low 21.64 USD
50-Day Moving Average 27.92 USD
200-Day Moving Average 28.47 USD

DNLI Share Statistics

Avg. Volume (3 month) 741.89K USD
Avg. Daily Volume (10-Days) 750.18K USD
Shares Outstanding 136.89M
Float 123.21M
Short Ratio 10.48
% Held by Insiders 14.58%
% Held by Institutions 79.22%
Shares Short 8.08M
Short % of Float 7.01%
Short % of Shares Outstanding 5.89%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -389.36%
Gross Margin -295.66%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -18.086%
Return on Equity (ttm) -39.32%

Income Statement

Revenue (ttm) 101.46M USD
Revenue Per Share (ttm) 0.79 USD
Quarterly Revenue Growth (yoy) -16.60%
Gross Profit (ttm) -250269000 USD
EBITDA -376710016 USD
Net Income Avi to Common (ttm) -370552000 USD
Diluted EPS (ttm) -2.83
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 1.29B USD
Total Cash Per Share (mrq) 9.41 USD
Total Debt (mrq) 57.09M USD
Total Debt/Equity (mrq) 5.91 USD
Current Ratio (mrq) 3.388
Book Value Per Share (mrq) 7.07

Cash Flow Statement

Operating Cash Flow (ttm) -231408992 USD
Levered Free Cash Flow (ttm) -100189128 USD

Profile of Denali Therapeutics

Country United States
State CA
City South San Francisco
Address 161 Oyster Point Boulevard
ZIP 94080
Phone 650 866 8548
Website https://www.denalitherapeutics.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 430

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Q&A For Denali Therapeutics Stock

What is a current DNLI stock price?

Denali Therapeutics DNLI stock price today per share is 20.09 USD.

How to purchase Denali Therapeutics stock?

You can buy DNLI shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Denali Therapeutics?

The stock symbol or ticker of Denali Therapeutics is DNLI.

Which industry does the Denali Therapeutics company belong to?

The Denali Therapeutics industry is Biotechnology.

How many shares does Denali Therapeutics have in circulation?

The max supply of Denali Therapeutics shares is 139.16M.

What is Denali Therapeutics Price to Earnings Ratio (PE Ratio)?

Denali Therapeutics PE Ratio is now.

What was Denali Therapeutics earnings per share over the trailing 12 months (TTM)?

Denali Therapeutics EPS is -1.06 USD over the trailing 12 months.

Which sector does the Denali Therapeutics company belong to?

The Denali Therapeutics sector is Healthcare.

Denali Therapeutics DNLI included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD